Literature DB >> 32086498

Considering the role of radical prostatectomy in 21st century prostate cancer care.

Anthony J Costello1.   

Abstract

The practice of radical prostatectomy for treating prostate cancer has evolved remarkably since its general introduction around 1900. Initially described using a perineal approach, the procedure was later popularized using a retropubic one, after it was first described as such in 1948. The open surgical method has now largely been abandoned in favour of the minimally invasive robot-assisted method, which was first described in 2000. Until 1980, the procedure was hazardous, often accompanied by massive blood loss and poor outcomes. For patients in whom surgery is indicated, prostatectomy is increasingly being used as the first step in a multitherapeutic approach in advanced local, and even early metastatic, disease. However, contemporary molecular insights have enabled many men to safely avoid surgical intervention when the disease is phenotypically indolent and use of active surveillance programmes continues to expand worldwide. In 2020, surgery is not recommended in those men with low-grade, low-volume Gleason 6 prostate cancer; previously these men - a large cohort of ~40% of men with newly diagnosed prostate cancer - were offered surgery in large numbers, with little clinical benefit and considerable adverse effects. Radical prostatectomy is appropriate for men with intermediate-risk and high-risk disease (Gleason score 7-9 or Grade Groups 2-5) in whom radical prostatectomy prevents further metastatic seeding of potentially lethal clones of prostate cancer cells. Small series have suggested that it might be appropriate to offer radical prostatectomy to men presenting with small metastatic burden (nodal and or bone) as part of a multimodal therapeutic approach. Furthermore, surgical treatment of prostate cancer has been reported in cohorts of octogenarian men in good health with minimal comorbidities, when 20 years ago such men were rarely treated surgically even when diagnosed with localized high-risk disease. As medical therapies for prostate cancer continue to increase, the use of surgery might seem to be less relevant; however, the changing demographics of prostate cancer means that radical prostatectomy remains an important and useful option in many men, with a changing indication.

Entities:  

Mesh:

Year:  2020        PMID: 32086498     DOI: 10.1038/s41585-020-0287-y

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  100 in total

1.  Retropubic prostatectomy.

Authors:  T MILLIN
Journal:  J Urol       Date:  1948-03       Impact factor: 7.450

2.  VIII. Conservative Perineal Prostatectomy: The Results of Two Years' Experience and Report of Seventy-Five Cases.

Authors:  H H Young
Journal:  Ann Surg       Date:  1905-04       Impact factor: 12.969

Review 3.  Landmarks in prostate cancer.

Authors:  Niranjan J Sathianathen; Badrinath R Konety; Juanita Crook; Fred Saad; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2018-10       Impact factor: 14.432

4.  Technical nuances and surgical results of radical retropubic prostatectomy in 150 patients.

Authors:  P H Lange; P K Reddy
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

5.  An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery.

Authors:  W G Reiner; P C Walsh
Journal:  J Urol       Date:  1979-02       Impact factor: 7.450

6.  Radical prostatectomy for the treatment of localized prostatic carcinoma.

Authors:  P C Walsh
Journal:  Urol Clin North Am       Date:  1980-10       Impact factor: 2.241

7.  Impotence following radical prostatectomy: insight into etiology and prevention.

Authors:  P C Walsh; P J Donker
Journal:  J Urol       Date:  1982-09       Impact factor: 7.450

8.  Management of recalcitrant bladder neck contracture after radical prostatectomy for prostate cancer. Endoscopic and open surgery.

Authors:  Benjamin N Breyer; Jack W McAninch
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

9.  Lead time associated with screening for prostate cancer.

Authors:  Magnus Törnblom; Henry Eriksson; Stefan Franzén; Ove Gustafsson; Hans Lilja; Ulf Norming; Jonas Hugosson
Journal:  Int J Cancer       Date:  2004-01-01       Impact factor: 7.396

10.  Bladder neck contracture after robot-assisted laparoscopic radical prostatectomy: evaluation of incidence and risk factors and impact on urinary function.

Authors:  Lambda P Msezane; W Stuart Reynolds; Ofer N Gofrit; Arieh L Shalhav; Gregory P Zagaja; Kevin C Zorn
Journal:  J Endourol       Date:  2008-01       Impact factor: 2.942

View more
  16 in total

Review 1.  Review of automated performance metrics to assess surgical technical skills in robot-assisted laparoscopy.

Authors:  Sonia Guerin; Arnaud Huaulmé; Vincent Lavoue; Pierre Jannin; Krystel Nyangoh Timoh
Journal:  Surg Endosc       Date:  2021-11-08       Impact factor: 4.584

Review 2.  CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.

Authors:  Lan Li; Liping Zhong; Chao Tang; Lu Gan; Tong Mo; Jintong Na; Jian He; Yong Huang
Journal:  Clin Transl Oncol       Date:  2022-02-15       Impact factor: 3.340

3.  The comparison of survival between active surveillance or watchful waiting and focal therapy for low-risk prostate cancer: a real-world study from the SEER database.

Authors:  Qi-Ming Yuan; Tian-Hai Lin; Kun Jin; Shi Qiu; Xiang-Hong Zhou; Di Jin; Jia-Kun Li; Lu Yang; Qiang Wei
Journal:  Asian J Androl       Date:  2022 May-Jun       Impact factor: 3.054

Review 4.  Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy.

Authors:  Sean F Mungovan; Sigrid V Carlsson; Gregory C Gass; Petra L Graham; Jaspreet S Sandhu; Oguz Akin; Peter T Scardino; James A Eastham; Manish I Patel
Journal:  Nat Rev Urol       Date:  2021-04-08       Impact factor: 14.432

5.  miR-96-5p, miR-134-5p, miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-archival samples study.

Authors:  Kacper Pełka; Klaudia Klicka; Tomasz M Grzywa; Agata Gondek; Janina M Marczewska; Filip Garbicz; Kinga Szczepaniak; Wiktor Paskal; Paweł K Włodarski
Journal:  Histochem Cell Biol       Date:  2020-12-17       Impact factor: 4.304

6.  Association of β-Blocker Use at Time of Radical Prostatectomy With Rate of Treatment for Prostate Cancer Recurrence.

Authors:  Shivanthe Sivanesan; Kristin Austlid Taskén; Helene Hartvedt Grytli
Journal:  JAMA Netw Open       Date:  2022-01-04

7.  Functional Preservation and Oncologic Control following Robot-Assisted versus Laparoscopic Radical Prostatectomy for Intermediate- and High-Risk Localized Prostate Cancer: A Propensity Score Matched Analysis.

Authors:  Wen Deng; Ru Chen; Ke Zhu; Xiaofeng Cheng; Yunqiang Xiong; Weipeng Liu; Cheng Zhang; Yulei Li; Hao Jiang; Xiaochen Zhou; Ting Sun; Luyao Chen; Xiaoqiang Liu; Gongxian Wang; Bin Fu
Journal:  J Oncol       Date:  2021-12-21       Impact factor: 4.375

8.  Transvesical Retzius-Sparing Versus Standard Robot-Assisted Radical Prostatectomy: A Retrospective Propensity Score-Adjusted Analysis.

Authors:  Wen Deng; Hao Jiang; Xiaoqiang Liu; Luyao Chen; Weipeng Liu; Cheng Zhang; Xiaochen Zhou; Bin Fu; Gongxian Wang
Journal:  Front Oncol       Date:  2021-05-17       Impact factor: 6.244

9.  Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial.

Authors:  Yu-Tian Xiao; Xianzhi Zhao; Yifan Chang; Xiaojun Lu; Ye Wang; Huojun Zhang; Shancheng Ren
Journal:  BMJ Open       Date:  2020-11-03       Impact factor: 2.692

Review 10.  Depression and prostate cancer: implications for urologists and oncologists.

Authors:  Christopher F Sharpley; David R H Christie; Vicki Bitsika
Journal:  Nat Rev Urol       Date:  2020-07-30       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.